Xceleron to lead EU Microdose AMS Partnership Programme

UK-based bioanalytical CRO Xceleron, which specialises in Accelerator Mass Spectrometry (AMS) services, has been asked to lead the European Union Microdose AMS Partnership Programme (EUMAPP).

The 30-month, Euro 1.2m project gathers together 10 organisations from five countries (UK, Sweden, Netherlands, France and Poland). The programme aims to certify high and low voltage AMS technologies as the most accurate, reproducible and appropriate methodologies for all measurements required by microdosing studies.

The microdosing approach conducted with AMS offers new ways of developing drugs by bridging the gap between the laboratory and the clinic. The EU-MAPP project will contribute to putting Europe at the forefront of microdosing by:

• demonstrating the reliability of the microdosing approach for predicting drugs' pharmacokinetics when used at pharmacological doses (from seven different biopharmaceuticals);

• certifying AMS as the most accurate, appropriate and powerful technology for reproducible measurements required by microdosing studies;

• developing in silico modelling application to predict phramacokinetic

parameters from data derived from microdosing studies

'We are delighted to be leading this European consortium which aims to further demonstrate to the pharmaceutical industry the merits of human microdosing as a science driven approach to drug development,' said Professor Colin Garner, Xceleron's ceo. 'This programme follows on from the successful CREAM trial and will add seven more drugs to the growing portfolio of compounds tested by Xceleron.'